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Abstract: Background: Widespread protein aggregation occurs in the living system under stress or 
during aging, owing to disturbance of endoplasmic reticulum (ER) proteostasis. Many neurodegen-
erative diseases may have a common mechanism: the failure of protein homeostasis. Perturbation of 
ER results in unfolded protein response (UPR). Prolonged chronical UPR may activate apoptotic 
pathways and cause cell death. 
Methods: Research articles on Sigma-1 receptor were reviewed. 
Results: ER is associated to mitochondria by the mitochondria-associated ER-membrane, MAM. 
The sigma-1 receptor (Sig-1R), a well-known ER-chaperone localizes in the MAM. It serves for 
Ca2+-signaling between the ER and mitochondria, involved in ion channel activities and especially 
important during neuronal differentiation. Sig-1R acts as central modulator in inter-organelle sig-
naling. Sig-1R helps cell survival by attenuating ER-stress. According to sequence based predic-
tions Sig-1R is a 223 amino acid protein with two transmembrane (2TM) domains. The X-ray struc-
ture of the Sig-1R [1] showed a membrane-bound trimeric assembly with one transmembrane 
(1TM) region. Despite the in vitro determined assembly, the results of in vivo studies are rather 
consistent with the 2TM structure. The receptor has unique and versatile pharmacological profile. 
Dimethyl tryptamine (DMT) and neuroactive steroids are endogenous ligands that activate Sig-1R. 
The receptor has a plethora of interacting client proteins. Sig-1R exists in oligomeric structures 
(dimer-trimer-octamer-multimer) and this fact may explain interaction with diverse proteins. 
Conclusion: Sig-1R agonists have been used in the treatment of different neurodegenerative dis-
eases, e.g. Alzheimer’s and Parkinson’s diseases (AD and PD) and amyotrophic lateral sclerosis. 
Utilization of Sig-1R agents early in AD and similar other diseases has remained an overlooked 
therapeutic opportunity. 
Keywords: Neurodegenerative diseases, sigma-1 receptor, pharmacology, agonist, DMT, antagonist, chaperone. 
1. INTRODUCTION: BRIEF HISTORY OF THE 
SIGMA-1 RECEPTOR 
 Neurodegenerative diseases (NDDs) are described as 
disorders with progressive loss of neuronal integrity, both 
structural and functional. Abnormal protein folding is widely 
believed to be coupled with neurodegeneration. Alzheimer’s 
and Parkinson’s disease (AD and PD) are the most common 
forms of NDDs; Lewy body disease (DLB), Huntington  
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disease (HD) and amyotrophic lateral sclerosis (ALS) are 
less frequent. Currently, only symptomatic treatments are 
available, which ameliorate the symptoms without halting or 
slowing the progression of disease. There is an urgent need 
to develop effective, disease modifying therapeutics to pro-
tect and restore neuronal integrity. The first step on this way 
is a better understanding of the pathomechanisms of NDDs 
for the selection of new drug targets. Among the putative 
targets for neuroprotection, recently the sigma-1 receptor 
(Sig-1R) has gained more and more attention. 
 The Sig-1R is an enigmatic protein with a unique amino 
acid sequence (homologous only to yeast sterol isomerases 
[2]), a unique pharmacological profile and a puzzling his-
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tory. Not long time ago, it has been classified as a member of 
the orphan receptors for which no endogenous ligand was 
known until the recent discovery of the endogenous hallu-
cinogen DMT (N,N-dimethyltryptamine) as its endogenous 
agonist [3]. Today, the Sig-1R is considered to be a non-G-
protein coupled, non-ionotropic intracellular chaperone at the 
endoplasmic reticulum (ER) that modulates Ca2+-signaling. 
 It has been a long way to arrive to this conclusion. The 
history of discovery of Sig-1R has existed for 40 years. 
Originally, Sig-1R was thought to be a member of the opioid 
receptor family. In 1976, Martin reported that the psychoto-
mimetic effects of SKF-10,047 (N-allylnormetazocine) in 
chronic spinal dogs do not originate from the µ and κ opioid 
receptors (named from the first letter of their selective 
ligands morphine and ketacozine, respectively). He proposed 
the introduction of a new type of the opioid receptors; sigma 
(from the first letter of SKF-10,047) [4]. This receptor was 
reported to be blocked by the universal opioid antagonist, 
naloxone. Later, Su identified a distinct binding site to medi-
ate the psychotomimetic effect of SKF-10,047 that was, 
however, insensitive to naloxone and naltrexone [5]. Mistak-
enly, the binding site was named sigma/opioid receptor; then 
the name was changed to sigma receptor [6]. Sig-1R was 
also defined as an NMDA (N-methyl-D-aspartate) receptor 
because phencyclidine (PCP) binds to the sigma receptor and 
(+)SKF-10,047 to the PCP-site of the NMDA receptor [7]. 
Radioligand binding studies identified two populations of the 
sigma binding sites (Sig-1 and Sig-2) that differ in their 
ligand selectivity, tissue and subcellular distribution [8, 9]. 
In recent years, significant achievements have been made in 
our understanding of the molecular basis of the Sig-1 sub-
type in normal and pathological conditions. The sigma-2 
subtype has remained more obscure due to the lack of suit-
able research tools (it has not yet been cloned). Sig-1 recep-
tors (the original sigma receptors) display high (nanomolar) 
affinity for the ‘unnatural’ (+) stereoisomer of benzomor-
phans https://en.wikipedia.org/wiki/Benzomorphan (e.g. 
SKF-10,047, pentazocine) and only low to moderate affini-
ties for (-) isomers. (+)-Pentacozine, the prototypic Sig-1R 
agonist binds with more than 100-fold selectivity to Sig-1 
versus Sig-2 binding sites, while 1,3-di-o-tolylguanidine 
(DTG) binds nearly equally well at both populations [10]. 
DTG in the presence of (+) pentazocine (to mask Sig-1 bind-
ing) has been the ligand of choice to study the Sig-2 subtype. 
In this review, we will focus on the Sig-1R type. The phar-
macology of the Sig-1R has been summarized in recent re-
views [11-17]. 
2. THE UNIQUE PROPERTIES OF SIG-1R: 
CHAPERONE FUNCTION, DISTRIBUTION, SUB- 
CELLULAR LOCALIZATION AND TRANSLOCA- 
TION 
 There are several properties of Sig-1R that make this 
protein unique among the receptors. The most important 
feature of Sig-1R: it is an intracellular receptor acting as a 
chaperone protein. The Sig-1R differs also structurally from 
the classical neurotransmitter receptors: although a trans-
membrane protein, it has only one transmembrane region [1]. 
(The results of in vivo studies are rather consistent with the 2 
transmembrane structure of Sig-1R. Sig-1R shows no post-
natal ontogeny and age-dependent increase of receptor den-
sity [18]. These properties and the widespread modulatory 
functions of Sig-1R underline the universal role of Sig-1R in 
cellular functions and cell survival. Alternative splicing  
results in the canonical isoform (223 amino acids) and 4 
other transcript variants (UniProt identifiers: Q99720-1 to 
Q99720-5) [19]. 
 Sig-1R has very versatile cellular function. Interestingly, 
the Sig-1R knock-out mice are viable and fertile, and do not 
show any apparent phenotype changes except for a reduced 
hypermotility response compared to wild-type mice [20]. 
Through regulation of lipid rafts, secretases, kinases, neu-
roreceptors and ion channels, the Sig-1R can influence signal 
transduction, citric acid cycle, oxidative stress, neuronal 
plasticity, etc. 
 The central nervous system (CNS) appears to be the pri-
mary site of Sig-1R activity and effects. Sig-1Rs are broadly 
spread in the CNS (e.g. hippocampus: highest density in den-
tate gyrus; hypothalamus, mesencephalon, olfactory bulb), in 
peripheral (abundantly in liver, kidney, lung, muscle), endo-
crine, immune and reproductive tissues [21]. At the cellular 
level, the Sig-1Rs are expressed in neurons, oligodendro-
cytes and ependymocytes. They are primarily found at the 
ER membranes that are physically associated with the mito-
chondria (MAM: mitochondria-associated ER membrane) 
[22] and are mainly associated with neuronal perikarya and 
dendrites [21, 23, 24]. 
 It is also unique that Sig-1R is a transmembrane protein 
which can dynamically translocate inside cells. Sig-1R local-
izes mainly at the MAM in ceramide-enriched microdo-
mains, apparently bound to ceramide [25]. Sig-1R also binds 
the binding immunoglobulin protein (BiP), another ER-
chaperone that prevents the translocation of Sig-1R [23]. 
Translocation of Sig-1Rs from the ER to the plasma mem-
brane (PM) has been reported [26], where Sig-1R interacts 
with many receptors, ion channels and kinases. Transloca-
tion occurs after stimulation of Sig-1R by agonists like co-
caine: the receptor can dissociate from BiP and translocate 
to the PM, the nuclear envelope and can interact with cyto-
sol proteins [27]. 
3. STRUCTURAL FEATURES OF THE SIG-1R 
 The heterogeneity of the sigma receptors and the lack of 
selective sigma ligands have greatly contributed to the diffi-
culties of the classification of this receptor type. The contro-
versy of the nature of sigma receptors was finally solved in 
1996 by the successful cloning of the Sig-1R gene from 
guinea pig liver [28]. It was demonstrated that the Sig-1R 
consists of 223 amino acids hypothetically with two putative 
transmembrane domains (TMDs) [29, 30]. The Sig-1R 
shares no sequence homology with any mammalian protein. 
However, it shares 60% amino acid identity to a yeast sterol 
isomerase, ERG2, although the mammalian Sig-1R does not 
have any enzyme activity [2, 31]. Subsequent cloning studies 
from a variety of tissues found 90% sequence conservation 
in mammalian species [32, 33]. The gene that encodes the 
human Sig-1R is located on chromosome 9p13 and contains 
four exons and three introns [34]. Hydropathy analysis of the 
Sig-1R described three hydrophobic regions [35]. Sequence-
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based algorithms that predict amino acid hydrophobicity 
(TMBase) have indicated two major hydrophobic helical 
transmembrane sequences (TMDI and TMDII) [29]. Former 
studies indicate that amino acid (AA) sequence 11-29 and 
92-112 represent the TMDI and TMDII, respectively. It is 
proposed that AA 29-92 forms a cytosolic loop and both the 
C- and N-termini are localized in the ER lumen [23, 36, 37]. 
More recent predictions show that TMDI spams between AA 
8 and 34, TMDII between AA 83 and 111 [38]. The Sig-1R 
orientation predicts that if the protein translocates into the 
plasma membrane, the C-and N-termini are located outside 
the cell. The so called steroid binding domain I and II 
(SBDL-I; SBDL-II) together with the TMDs and the C-
terminus have been revealed to be essential for ligand bind-
ing [39-41]. (The SBDL regions are thus named because of 
sequence homology to yeast sterol isomerase.) Photolabeling 
studies of A. Pal, et al. suggest that SBDL-I and SBDL-II 
regions of Sig-1R may be involved in forming a Sig-1R 
ligand binding site [42]. The 50AA cytosolic loop between 
the TMDI and TMDII has been studied by NMR and pro-
posed to contain 3 short helical regions [38]. A model of the 
key structural motifs of Sig-1R was published by Ortega-
Roland as well as U.B. Chu and A.E. Ruoho [43]. An excel-
lent review summarizes our present knowledge about the 
Sig-1R structure [44]. 
 Very recently, the first crystal structure of the full-length 
human Sig-1R was reported in complex with two chemically 
divergent ligands, PD144418 (a high affinity and selective 
sigma-1 antagonist) and 4-IBP (agonist or inverse agonist) 
[1]. The structure reveals a triangular organization compris-
ing three tightly associated protomers, each with a single 
transmembrane domain at the corner of a trimeric triangle. 
The C-terminal domain of the receptor shows an extensive, 
flat, hydrophobic membrane-proximal surface, the cytosolic 
surface is polar. Receptor binding would occur through a 
charge-charge interaction with the highly conserved Glu172, 
consistent with previous site-directed mutagenesis studies 
identifying this residue as essential for ligand binding [1, 45, 
46]. However, this crystal structure of the Sig-1R was gained 
by an in vitro approach of embedding the receptor in lipid-
containing nanodiscs. The discrepancy between the se-
quence-based prediction (two transmembrane) and X-ray 
(one transmembrane) structures suggests that the in vitro 
crystal structure not accurately represents the in vivo struc-
ture. The structure differences may indicate a potentially 
amorphous intrinsically disordered in vivo structure for the 
Sig-1R. 
 Previous biochemical and cellular studies suggest that 
oligomerization is a key functional property of this receptor 
and may be linked to ligand efficacy [1, 47, 48]. Sig-1R ex-
ists in rat liver membrane in oligomeric form [42]. Forster 
resonance energy transfer (FRET) analyses have shown that 
Sig-1R exists constitutively in monomeric and oligomeric 
(dimer-trimer-octamer-multimer) form [49]. Dimer and 
monomer forms of Sig-1R were favored in the presence of 
agonist (+)-pentazocine. Simultaneous studies demonstrated 
the presence of higher order oligomers favored by the Sig-
1R antagonist haloperidol. A hypothetic mechanistic model 
of Sig-1R oligomerization proposes that agonists create 
functionally active dimers and/or monomers from higher 
order oligomers [48]. Putative antagonists (or inverse ago-
nists) shift the equilibrium to the tetramer/oligomer forms, 
and thus higher oligomers might represent a reservoir for the 
active form. 
 The receptor as a chaperone protein is able to accommo-
date many client proteins (Tables 2 and 3), and tolerates very 
different structure of binding clients. The C-terminal tail 
(amino acid sequence 110-123) possesses chaperone func-
tions [23, 50]. The mystery, why Sig-1R has so many inter-
acting proteins (Tables 2 and 3) can be dissolved with the 
activity of alternately spliced variants of Sig-1 R or the inter-
action oligomeric structures of the receptor with proteins. 
The hypothetical IDP character of Sig-1R might explain the 
receptor structure stabilization by trimerization (in mem-
brane environment) and interactions with the co-chaperone 
BiP [38]. 
4. SIG-1R AGONISTS, ANTAGONISTS AND 
ALLOSTERIC MODULATORS 
 An intriguing feature of the Sig-1R is that it binds ligands 
with very diverse structures. These include small molecules 
that also interact with other targets, such as haloperidol, dex-
trometorphan, metamphetamine, verapramil, chloroquine, 
fluoxetine, donepezil, etc. Specifically, a majority of antip-
sychotics possess high to moderate binding affinities to Sig-
1R [51]. Based on extensive structure-activity relationship 
studies, Glennon et al. published a simple pharmacophore 
model for small molecule binding to the Sig-1R [52]. He 
postulated that the binding site consists of a basic amine site 
separated by two hydrophobic regions. The primary hydro-
phobic region is optimally an N-arylalkyl group and is situ-
ated at four-to six-carbons (6-10 Å), and a second hydropho-
bic domain 1- to 3-carbon apart (2.5-4 Å) from the obligate 
nitrogen. The unique hydrophobic nature of the ligand bind-
ing site enables hydrophobic moieties to associate with the 
binding site. Indeed, most Sig-1R ligands possess hydropho-
bic or amphipathic property (e.g., haloperidol and fluvoxam-
ine) and are positively charged. The neuroactive steroids 
(e.g. DHEA, progesterone), that induce several of their 
physiological effects through sigma receptors and are hy-
pothesized to be endogenous ligands for them, were shown 
to bind with moderate to weak binding affinities at this site 
[6]. Interestingly, this steroid does not have a nitrogen atom. 
The endogenous ligand for the Sig-1R has not been une-
quivocally identified yet, but the endohallucinogen DMT and 
sphingosine have also been postulated [3, 6, 53]. 
 The molecular basis of ligand efficacy is yet to be solved. 
Different methods are used in Sig-1R binding studies and no 
standard method of characterization has been chosen. The 
efficacy (agonist, antagonist) is not an absolute property of 
the ligand, it is influenced by the methods and tissues of the 
measurements. By convention, Sig-1R ’agonists’ are those 
compounds that induce the typical Sig-1R effects in whole-
animal physiologic studies or resemble the phenotypes of 
receptor overexpression. Selective Sig-1R agonists include: 
(+)-pentazocine, dehydroepiandrosterone, (+)-SKF10,047, 
PRE-084 (2-morpholin-4-ylethyl-1-phenyl- cyclohexane-1-
carboxylate), and SA4503 (1-[2-(3,4-dimethoxyphenyl) 
ethyl]-4-(3-phenylpropyl)piperazine). ’Antagonists’ are those 
compounds that generally have no effects on their own, but 
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attenuate the effects of Sig-1 stimulation or resemble the 
results of the gene knock-down. Sig-1R antagonists that are 
commonly cited in the literature include: progesterone, 
haloperidol, BD1047 (N-[2-(3,4-dichlorophenyl)ethyl]-N-
methyl-2-(dimethylamino) ethylamine), BD1063 (1-[2-(3,4-
dichlorophenyl)ethyl]-4-methylpiperazine), and NE-100 (4-
methoxy-3-(2-phenylethoxy)-N,N-dipropylbenzeneethan- 
amine). The involvement of the Sig-1 subtype in a given 
system requires careful analysis and verification using selec-
tive genetic and pharmacological tools. Several known drugs 
(e.g. SKF 83959, an atypical dopamine receptor-1 agonist) 
potentiate the binding of (+)-pentazocine to Sig-1R by allos-
teric manner [54]. SKF 83959 also inhibits microglia medi-
ated inflammation [55]. SOMCL-668 (3-methyl-phenyl-
2,3,4,5-tetrahydro-1H-benzo(d)azepin-7-ol), the latest identi-
fied novel and selective allosteric modulator of Sig-1R dis-
plays anti-seizure and antidepressant activity [54, 56]. 
 A complete list of Sig-1R ligands is difficult to obtain, as 
many compounds only have been used in pharmaceutical 
research and are not available, due to drug development. A 
very useful summary of the pharmacological properties of 
Sig-1R ligands were published by E.J. Cobos et al. [57].  
Table 1 shows the short list of the most important Sig-1R 
agonists, antagonists and allosteric modulators. 
5. SIG-1R INTERACTIONS WITH PROTEINS AND 
LIPIDS. MECHANISMS OF ACTION 
 The chaperone activity and the specific 3D barrel struc-
ture [1] of Sig-1R may answer the question why the Sig-1R 
has so many client proteins. The lists of these proteins are 
given in Tables 2 and 3 [14, 58]. The Sig-1Rs have been 
shown to play a role in numerous phenomena including car-
diovascular function, drug abuse, schizophrenia, clinical 
Table 1. A short list of Sig-1R ligands (agonists and antagonists). 
Agonists Refs. Other Activities 
N,N-Dimethyltryptamine (DMT) [3, 172, 173] 5HT2A receptor agonist 
(+)-N-allylnormetazocine ((+)-SKF 10,047) [51] NMDA receptor ligand 
2-(4-morpholino)ethyl-1-phenylcyclohexane-1-carboxylate (PRE-084) [23, 174] ̶ 
1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine (SA 4503, cutamesine) [175] ̶ 
4-phenyl-1-(4-phenylbutyl)piperidine (PPBP) [176] nNOS inhibition 
1-(2,8-Dimethyl-1-thia-3,8-diazaspiro(4,5)dec-3-yl)-3-(1H-indol-3-yl)propan-1-one 
(AF710B) 
[123] allosteric M1 agonist 
Dehydroepioandrosterone (DHEA) [177] neurosteroid, nuclear receptors 
Donepezil [128, 178, 179] cholinesterase inhibitor 
Amitriptyline [180] neurotransmitter reuptake blocker 
Fluvoxamine [23, 36, 181, 182] 5HT reuptake inhibitor 
Memantine [183] NMDAR antagonist 
Ifenprodil [184] NMDAR antagonist, α-1 antagonist 
(+)-Pentazocine  [23, 185, 186] ̶ 
Cocaine [23, 187] neurotransmitter reuptake blocker 
Dextromethorphan (DEX) [30, 188] NMDAR allosteric antagonist 
Antagonists  
N-(2-(3,4-dichlorophenyl)-N-methyl-2-(dimethylamino)ethylamine (BD 1047) [189] β-adrenoreceptor ligand 
1-(2-(3,4-dichlorophenyl)ethyl)-4-methylpiperazine (BD 1063) [189] ̶ 
4-Methoxy-3-(2-phenylethoxy)- 
N,N-dipropylbenzeneethaneamine (NE-100) 
[23] ̶ 
Progesterone [23] neurosteroid, progestogen 
Haloperidol [23] D2 and D3 antagonist 
Verapamil [190] Ca2+-antagonist, slow channel blocker 
Sertraline [60] 5HT reuptake inhibitor 
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depression, cancer and modulate mood disorders, amnesic 
and cognitive deficits as well as potentiate analgesia [6, 11, 
16, 59]. They are now considered as ligand-regulated mo-
lecular chaperones (for a review see [22, 60] of which the 
main physiological function is modulation of intracellular 
calcium signaling [23], inhibition of voltage-gated K+- chan-
nels [13, 30, 61], and release of various neurotransmitters 
including acetylcholine and glutamate [62]. Sig-1R is inti-
mately involved with the glutamate system and seems to be 
an essential part of the excitotoxicity. Sig-1R is implicated in 
cellular differentiation, neuroplasticity, neuroprotection and 
cognitive functioning of the brain [11, 63]. The signal trans-
duction pathways of these phenomena have not been clari-
fied yet. Sig-1 antagonists, but not agonists were shown to 
display GTP- and suramine sensitive high affinity binding 
implying coupling of the receptor to G-proteins [64]. Early 
radioligand binding studies showed that the binding of Sig-1 
ligands was altered by GTP and its analogues [65]. Contrary, 
evidence was published that the Sig-1R is not coupled to G-
proteins [66]. Sig-1R has a high tendency to form heterodi-
mers with other proteins, e.g. receptors, ion channels. The 
recent crystallization studies of the Sig-1R did not find any 
structure similarity of Sig-1R to the 7 transmembrane 
GPCRs [1]. The Sig-1R appears in a complex with voltage 
gated K+-channels (Kv1.4 and Kv1.5), leading to the idea that 
these receptors are auxiliary subunits [61]. There is evidence 
that Sig-1Rs are intracellular signal transduction amplifiers 
[67], regulators of inter-organelle communication [27, 68] or 
pluripotent modulators [14]. 
 Sig-1R integrates many signaling pathways and in par-
ticular modulates Ca2+ signaling through the inositol triphos-
phate (IP3) receptor between the ER and mitochondria [23]. 
Its participation is important in other ion channel and related 
receptor (K+ channel, NMDA receptor) activities as well, in 
lipid transport and metabolism, especially during neuronal 
morphogenesis and differentiation. The ER-mitochondrion 
border at the MAM – where the Sig-1R resides – serves as 
an important subcellular interface in the regulation of cellu-
lar survival by enhancing the stress-response signaling [69]. 
Sig-1R protects the cells against reactive oxygen species 
(ROS) and activates the antioxidant response elements [70], 
therefore Sig-1R agonists may function as indirect antioxi-
dants. The induction of Sig-1R can repress cell death signal-
ing: up-regulation of Sig-1R suppresses the apoptosis caused 
by ER stress [71]. Tryptaminergic trace amines (like DMT) 
as well as neurosteroids (e.g. dehydroepiandrosterone, 
pregnenolon) are endogenous ligands that activate the Sig-
1R [3] and are expected to elicit the described effects. 
 The ER chaperone function of the Sig-1R is essential for 
metabotropic receptor signaling and for survival against cel-
lular (particularly ER) stress. Dysfunctional chaperones are 
Table 2. Sig-1R interacting proteins (direct interactions) [14]. 
Plasma membrane proteins: 
 Acid-sensing ion channels (ASICs) 
 Dopamine receptors (D1R, D2R) 
 Muscarinic acetylcholine receptor (mAchR) 
 Mu-Opioid receptor (MoR) 
 NMDA receptor (subunit1) 
 Cannabinoid receptor1 (CB1R) 
 Tropomyosin receptor kinase B (Trk B) 
 Platelet-derived growth factor receptor (PDGFR) 
 Integrin-D1 
 Voltage-gated potassium channels (Kv) 
 Voltage-gated sodium channels (Na v ) 
Cytosol proteins: 
 Cell engulfment and motility domain (ELMOD) 
 Ras-related C3 botulinum toxin substrate (Rac)-GTPase 
ER-mitochondrion interface (MAM) and mitochondrial proteins 
 Binding immunoglobulin protein (BiP) 
 Inositol 1,4,5-triphosphate receptor Type 3 (IP3R3) 
 Ankyrin 
 Voltage-dependent anion channels (VDAC) 
 Inositol-requiring enzyme (IRE1) 
 Insulin-induced gene (Insig) 
Nuclear envelope proteins 
 Emerin 
 Ran-binding protein (RanBP2) 
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Table 3. Proposed Sig-1R interacting proteins revealed by bioinformatics analyses [58]. 
Plasma membrane proteins 
 PDZ-domain containing 11 (PDZD11) 
 Transmembrane 7 superfamily member 2 (TM75F2) 
Citoplasm proteins 
 Eukaryotic translation initiation factor 5A (EIF5A) 
 Heat shock 70-kDa protein5 (HSPA5) 
 Nascent polypeptide-associated complex α-subunit 2 (NACA2) 
 RNA export 1 homolog (RAE1) 
 Ribosomal protein S27a (RPS27A) 
 Sec61 α-2 subunit (SEC61A2) 
 Ubiquitin A52 residue ribosomal protein fusion product1 (UBA52) 
 Ubiquitin C (UBC) 
 Exportin 1, CRM1 homolog (XP01) 
 Exportin (tRNA) (XPOT) 
ER membrane 
 Ancient ubiquitous protein1 (AUP1) 
 Chromosome 14 open reading frame (C14 orf1) 
 Cytochrom P450, family 51 (CYP51A1) 
 Eukaryotic translation initiation factor 5A (EIF5A) 
 Glucosidase, α, neutral AB (GANAB) 
 Hydroxysteroid (17-β) dehydrogenase 12 (HSD17B12) 
 Nascent polypeptide-associated complex α-subunit 2 (NACA2) 
 NAD(P) dependent steroid dehydrogenase-like (NSDHL) 
 Retinol dehydrogenase 11 (RDH11) 
 Ribophorin II (RPN2) 
 Sterol-C4-methyl oxidase like (SC4MOL) 
 Sec61 α-2 subunit (SEC61A2) 
 Squalene epoxidase (SQLE) 
 Surfeit 4 (SURF4) 
 Transmembrane 7 superfamily member 2 (TM75F2) 
Mitochondria 
 Cytochrome c-1 (inner membrane) (CYC1) 
 Prohibitin (inner membrane) (PHB) 
 Solute carrier family 25, member 39 (inner membrane) (SLC25A39) 
 Solute carrier family 25, member 11 (inner membrane) (SLC25A11) 
 Voltage dependent anion channel 2 (outer membrane) (VDAC2) 
Nucleus 
 Exportin 1 (XP01) 
 Exportin (tRNA) nuclear export receptor for tRNAs (XPOT) 
 Cytochrom c-1 (CYC1) 
 Eukaryotic translation initiation factor 5A (EIF5A) 
 Lamin B receptor (LBR) 
 Nascent polypeptide-associated complex α-subunit 2 (NACA2) 
 Nucleoporin 205 kDa (NUP205) 
 RNA export 1 homolog (RAE1) 
 Ribosomal protein S27 (RPS27A) 
 Ubiquitin A52 residue ribosomal protein fusion product1 (UBA52) 
 Ubiquitin C (UBC) 
The Role of Sigma-1 Receptor, an Intracellular Chaperone Current Neuropharmacology, 2018, Vol. 16, No. 1    103 
 
responsible for numerous diseases [72], especially the neu-
rodegenerative ones. Sig-1R has so far been implicated in 
illnesses like AD [73, 74], PD [75], cancer [76], cardiac con-
ditions [77] retinal dysfunction, perinatal and traumatic brain 
injury, ALS, HIV-related dementia, major depression, and 
psychostimulant addiction [78]. In addition, Sig-1R muta-
tions have been implicated in frontotemporal lobar degenera-
tion (FTLD) and ALS [79]. How Sig-1R may relate to this 
plethora of diseases remains to be clarified but its protective 
influence has been verified on various aspects of cellular 
processes, such as Ca2+ signaling, mitochondrial functions, 
ER stress, apoptotic pathways, and tumor cell proliferation 
[12]. As Sig-1Rs are expressed in the immune system, im-
munomodulatory functions have also been reported in the 
literature [80, 81]. Although the interaction of Sig-1R in dif-
ferent tissues is very complex, apparently Sig-1R plays a 
central role in neurotransmission and apoptosis. The devel-
opment of new knockout mice and transgenic lines will fa-
cilitate further research. 
6. SIG-1R AS A PLURIPOTENT MODULATOR IN 
CELLS 
 The ER-chaperone Sig-1R resides at then MAM where it 
supports survival of cells by controlling Ca-signaling from 
the ER to mitochondria via the IP3 receptor. Simultaneously, 
Sig-1R attenuates free radical damage via Nrf2 signaling. 
Sig-1R agonists facilitate receptor translocation from the 
MAM to the PM. The translocation of Sig-1R makes possi-
ble the interaction with (and regulation of) many other cyto-
solic or membrane-bound functional proteins, e.g. receptors, 
ion channels and kinases (Tables 2 and 3). Another translo-
cation of Sig-1R from MAM to the nucleus membrane pro-
vides the possibility for interaction with chromatine-
remodeling factors and thus transcriptional regulation of 
genes. Dysfunction of Sig-1R may have a role in disorders 
and thus the receptor provides novel therapeutic opportuni-
ties to treat these diseases. 
 Possessing both chaperone and receptor functions and the 
versatility of its targets the Sig-1R represents a pluripotent 
modulator in the living systems and is involved in the etiopa-
thology of many diseases [14]. As a consequence, the actions 
of Sig-1R might be apparent only under abnormal state in the 
cells, e.g. at the beginning of a disease when big changes call 
Sig-1R to assist and maintain cell homeostasis. Sig-1R ago-
nists function selectively only under pathological conditions 
thus limiting adverse side effects and have a favorable safety 
profile. 
7. COMMON MECHANISMS OF NEURODEGENE- 
RATION 
 NDDs as diverse as AD, PD, ALS-FTLD, HD, retinal 
degeneration and stroke share common cellular and molecu-
lar pathological mechanisms such as excitotoxicity, calcium 
dysregulation and oxidative stress, mitochondrial dysfunc-
tion and ER stress. Dysfunction of glial cells may also con-
tribute to neurodegeneration. 
 Fundamental cellular functions demand regulated protein 
folding homeostasis. Formation of misfolded proteins that 
may associate to toxic assemblies is the common feature of 
neurodegenerative disease. ER is the subcellular organelle 
with the function of folding and modifying secretory and 
membrane proteins. 
 Formation of misfolded proteins and toxic aggregates 
point to the common pathway of NDDs: failure in normal 
protein folding [82]. Growing evidence suggests that (be-
sides other cellular stress mechanisms) mainly ER-stress 
contributes to the development of diseased state of neurons. 
Chronic ER-stress and activation of unfolded protein re-
sponse (UPR) may result in impaired Ca2+- and redox-
homeostasis and oxidative stress disturbing vital mitochon-
drial functions. Intracellular Ca2+, released from ER, in-
creases mitochondrial ROS production and further accumu-
lation of ROS within ER and mitochondria, disturbing their 
vital functions. Chronic ER stress may also induce inflam-
matory processes through the UPR pathways. These events: 
ER-stress, oxidative stress triggered by ROS-production as 
well as mitochondrial dysfunction and inflammation together 
form a molecular web that is associated with a wide range of 
diseases including NDDs [83]. 
7.1. ER-stress and Unfolded Protein Response 
 ER function can be altered in different ways and ER 
stress can be caused by a defective (mutated) mitochondrion, 
hypoxia, hyperglycemia, hyperlipidemia, viral infections, 
disturbances in cellular Ca2+ levels, redox regulation, or by 
oxidative stress. These so-called stress signals exhaust the 
ER machinery and result in buildup of unfolded proteins. An 
adaptive process called UPR is triggered with an aim to re-
store ER homeostasis. Originally, UPR has a cell protective 
effect: it prevents overload of the ER lumen with newly syn-
thesized proteins and activates degradation of misfolded pro-
teins. However, if the stress signal is severe and/or pro-
longed, misfolded proteins enter the mitochondria and cause 
dysfunction in energy production [82, 84]. As a result, cell 
death pathways are triggered in the form of apoptotic and 
pro-inflammatory reactions [85], as it will be detailed below. 
 Fig. 1. shows that three major pathways mediate the 
UPR: protein kinase RNA-like kinase (PERK), inositol re-
quiring enzyme 1 (IRE1a) and activating transcription factor 
6 (ATF6). Sustained activation of PERK triggers a signaliza-
tion cascade leading to C/EBP homologous protein (CHOP) 
upregulation, this process inhibits the expression of anti-
apoptotic B-cell lymphoma 2 (Bcl-2) and upregulates the 
pro-apoptotic BH3-only proteins. These events result in trig-
gering Bak- (Bcl-2 homologous antagonist killer) and Bax 
(Bcl-2 like protein 4)-dependent apoptosis [86]. 
 IRE1a may induce another signalization cascade leading 
to activation of c-JUN amino terminal kinase (JNK) and 
apoptosis signal regulating kinase (ASK), both of them trig-
ger caspase activation and apoptotic cell death. 
 ATF6 activation can also decrease Bcl-2 level and in-
crease cytochrom-C release, contributing to the activation of 
the apoptotic cascade [87]. 
 In summary, UPR is a bifunctional cellular response to 
protein misfolding, possessing both pro- and anti-survival 
effects. Basal activity of the UPR is beneficial by activating 
the ER-assisted degradation (ERAD) machinery for clearing 
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misfolded proteins by the ubiquitin-proteasoma system and 
autophagy. However, sustained ER stress and chronic UPR 
could trigger rather a cell death than cell maintenance pro-
gram [88]. Chronic ER-stress response might be linked to 
NDDs such as AD, PD and HD [86, 89]. 
 Malfunction of the “ER stress – UPR – mitochondrial 
function - ROS production” web is central to a large diver-
sity of illnesses. Growing evidences suggest ER stress with 
UPR as being a cardinal component in the development of 
many pathological conditions [90, 91]. Chronic UPR is 
thought to play a key role in neurodegenerative diseases and 
in many illnesses of civilization such as, diabetes, cancer, 
atherosclerosis, autoimmune, and cardiovascular disorders 
[83]. All of these disorders may have common pathological 
components: deficits in ER-proteostasis which lead to mis-
folded proteins accumulation characteristic of NDDs [86, 
92]. Targeting Sig-1R by agonists may regulate ER stress 
and UPR, manage ER perturbations, regulate the formation 
of toxic misfolded proteins, and prevent the cell-killing 
apoptotic pathways (Fig. 1) [93]. Similar effects are expected 
from the endogenous Sig-1R ligands. 
7.2. Mitochondrial Dysfunction and Ca2+-overload of 
Cells 
 Mitochondria play critical roles in neuronal maintenance 
by generating ATP and biosynthetic substrates, regulating 
Ca2+-homeostasis and initiating apoptosis. Mitochondrial 
dysfunction is associated with NDDs [94, 95]. According  
to the most recent models, ATP insufficiency and Ca2+-
dysregulation are the initial triggers of the excitotoxic cas-
cade. 
 Mitochondrial fission and fusion are parts of normal or-
ganellar maintenance and particularly significant in axons. 
ER was identified as a crucial component of the fission ma-
 
Fig. (1). Sig-1R regulation of the three signal pathways of ER-stress activated UPR. ER chaperone BiP/GRP78 under normal conditions 
binds all the three ER-stress sensors (PERK: protein kinase RNA like ER-kinase; IRE1α: inositol requiring enzyme 1α; ATF6: activating 
transcription factor 6). Under ER-stress BiP dissociates from sensors. PERK and IRE1α will be phosphorylated and oligomerized, ATF6 
translocates to the Golgi.(Abbreviations: eIF2α: eukaryotic translation initiation factor 2α; XBP1: X-box binding protein 1 (spliced form); 
TRAF2: TNF-associated factor-2; ATF4: transcriptional activator factor-4; MT: mitochondrion; CHOP: c/EBF homologous protein; Bcl-2: 
B-cell lymphoma 2; Bax: Bcl-2 like protein 2; Bak: Bcl-2 homologous antagonist killer; JNK: c-Jun terminal amino kinase; ASK1: apoptosis 
signal regulating kinase). Sig-1R activation increases cell survival by decreasing the activation of PERK, ATF6 and IRE1α as well as lower-
ing pro-apoptopic response (CHOP, Bax, Bak) and increases anti-apoptopic Bcl-2 activity. 
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chinery [96]. Fragmented mitochondria and increased fission 
activity are associated with NDDs such as AD, PD and HD 
[95]. The common membrane site MAM is very important in 
lipid synthesis and trafficking, Ca2+-homeostasis and regula-
tion of mitochondria-triggered apoptosis. Mitochondria-
MAM dysregulation was proposed as one of the underlying 
causes of AD, contributing to neuronal loss [97, 98]. 
 Sustained activation of NMDA receptors increases intra-
cellular Ca2+ level, followed by failure in Ca2+-homeostasis. 
Activation of mitochondrial permeability transition pore 
opening is triggered by Ca2+-uptake into the mitochondrial 
matrix [99]. Continuous release of glutamate causes persis-
tant activation of the NMDA receptors, leading to neuronal 
excitotoxicity. Excess of intracellular Ca2+ may contribute to 
neurodegeneration in many NDDs such as AD, PD and ALS 
[100-102]. 
7.3. Oxidative Stress 
 ROS are generated under different conditions, e.g. mito-
chondrial dysfunction and production by glial cells. Neurons 
are particularly vulnerable to glial stress [103]. Oxidative 
damage can affect proteins, nucleic acids and lipids. Detec-
tion of increased ROS production and oxidative damage in 
NDDs such as AD and PD is the best evidence for the causa-
tive effect of ROS [94, 103]. Oxidative stress also decreases 
the production of ATP and the antioxidant capacity (e.g. the 
level of reduced coenzymes) by impairing mitochondrial 
function [94]. 
7.4. Neuroinflammation, Reactive Gliosis 
 Reactive astrogliosis, the activation of astrocytes leads to 
increased expression of certain genes, e.g. glial fibrillary 
acidic protein (GFAP). Upregulation of GFAP causes astro-
cyte proliferation, then astrocyte migration and production of 
cytokines, chemokines and neurotrophic factors that aggra-
vate brain damage. 
 Microglial cells are macrophage-derived resident im-
mune cells of the CNS. As a result of dyshomeostasis in 
CNS, microglia is activated similarly to macrophages in the 
periphery showing pro-inflammatory (M1) and anti-
inflammatory (M2) responses. Pro-inflammatory microglial 
response can cause damage to the CNS, through the release 
of ROS and pro-inflammatory cytokines [104]. Limiting of 
the inflammatory M1 and enhancing of reparative M2 re-
sponses are desired for neuroprotection. 
8. NEUROPROTECTIVE ACTIONS BY SIG-1R 
LIGANDS 
8.1. Modulation of the ER and Mitochondrial Function 
 Sig-1R as a chaperone modulates UPR (Fig. 1). Under 
normal conditions Sig-1R is in dormant state in MAM form-
ing a complex with another ER-chaperone BiP [25]. After 
ER stress or ligand stimulation Sig-1R dissociates from BiP 
and modulates the activities of the 3 major branches of UPR 
(PERK, IRE1a, ATF6). ER stress is also associated with the 
upregulation of Sig-1R expression. 
 Sig-1R overexpression increases cell survival by decreas-
ing the activation of PERK and ATF6, probably with direct 
protein-protein interaction. Low activity of Sig-1R destabi-
lizes the conformation of IRE1a and decreases cell survival 
[105]. 
 Sig-1R ligands ameliorate mitochondrial function, e.g. 
the agonist BHDP protected rat liver cells. Another agonist, 
SA4503 protected cardiomyocytes from ischemic stress. Sig-
1R agonists preserved mitochondrial respiration and ATP 
synthesis [106, 107]. Under ER-stress Sig-1R dissociates 
from the BiP complex, then interacts directly with IP3R3 and 
stabilizes its structure. IP3R3 in turn promote Ca2+-uptake 
and cell survival [23]. 
 Sig-1R may also regulate the pro- and anti-apoptotic sig-
nals that target mitochondria: the receptor activation in-
creases Bcl-2 expression, the elevated level of Bcl-2 interacts 
with IP3R thus increasing IP3R-mediated mitochondrial Ca2+-
uptake and ATP production [108, 109]. 
8.2. Attenuation of ROS Production 
 Increased oxidative damage was demonstrated in the tis-
sues of Sig-1 knockout or knockdown mice [70]. Activation 
of Sig-1R decreases ROS-accumulation probably via the 
modulation of ROS-neutralizing proteins, upregulation of 
antioxidant response elements (NAD(P):quinine oxidoreduc-
tase1 (NQO1), superoxide dismutase (SOD). 
8.3. Ca2+-homeostasis and Glutamate Activity 
 Activation of Sig-1Rs may dampen the excitotoxic effect 
of glutamate (Glu). Excessive Glu effects can be pronounced 
during acute events such as ischemic stroke and trauma, or 
milder but prolonged in chronic NDDs such as AD, PD, HD 
and ALS [110]. 
 The regulation of intracellular Ca2+ homeostasis is one of 
the major mechanisms by which Sig-1R ligands perform 
neuroptotection. (+)-Pentazocine modulates the sustained 
Ca2+-flux at toxic concentration of glutamate in primary rat 
cortical neurons [111]. Sig-1R agonists attenuate intracellu-
lar Ca2+ elevation in the Na-azide--glucose deprivation 
ischemia model [112]. Sig-1R interacts in cell survival by 
normalization of ER-Ca2+ concentrations by promoting Ca2+-
entry into mitochondria through stabilization of IP3R3 recep-
tors [23]. Activation of Sig-1Rs under certain conditions 
inhibits NMDA receptors, which are the principal mediators 
of excitotoxic damage [101, 113]. 
8.4. Modulation of Glial Activity 
 Sig-1R ligands may ameliorate reactive astrogliosis in 
rodent models of stroke and ALS [114, 115]. Similarly, Sig-
1R ligands modulate microglial activity in animal models of 
PD and ALS, affecting both M1 and M2 type microglial re-
sponses [102, 115, 116]. Sig-1R elicits neuroprotective and 
neurorestorative effects by balancing the inflammatory and 
reparative microglial responses: treating an ALS model ani-
mal with PRE-084 increased the number of glial cells asso-
ciated with neuronal repair [115]. 
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9. THERAPEUTIC APPLICATION OF SIG-1R 
MODULATION 
 A short list of preclinical studies and clinical trials of the 
cytoprotective effect of Sig-1R agonists are summarized in 
(Table 4). 
9.1. Alzheimer’s Disease 
 AD is a very complex, multifactorial disease of heteroge-
neous genetic and environmental background, characterized 
by severe cognitive impairment and memory loss [117]. The 
pharmacology of Sig-1R and its role in AD was widely re-
viewed in 2009 [11] and in 2015 [13]. Functional deficiency 
of Sig-1R plays an important role in the β-amyloid (Aβ) in-
duced neuronal loss. Certain genetic combinations of Sig-1R 
and apolipoprotein E (apo-E) genotypes synergistically in-
crease the risk of AD [118]. Sig-1R genotype is a determin-
ing risk factor in sporadic AD [73]. 
 Sig-1R levels do not change considerably during normal 
ageing [62], however, in brains and postmortem tissues of 
Table 4. A short list of preclinical and clinical trials with cytoprotective Sig-1R agonists. 
Disease/Drug Candidate Drug Activities Preclinical Studies Refs. Clinical Trials 
(Phase 1,2,3) 
Refs. 
Afobazole Sig-1R agonist, 
melatonin (MT3) 
agonist 
Neuron culture 
Mice, icv Aβ 25-35 
(AD model) 
[59, 121, 122] - - 
AF710B Sig-1R agonist,  
M1 agonist 
AD mouse model [123] - - 
Anavex 2-73 Sig-1R agonist,  
M1 agonist 
Mice, icv Aβ 25-35 [124] - - 
Anavex 2-73 - - - Phase 1  
(max. dose 55mg) 
Phase 2a  
(oral, iv adm) 
www.anavex.com 
Anavex 2-73+ 
Donepezil 
ChE-ase inhibitor Mice, icv Aβ 25-35 
(AD model) 
[126] - - 
AD 
Anavex Plus 
(combination of 
Anavex 2-73 plus 
Donepezil) 
- Synergistic effect in AD 
disease models 
www.anavex.com A patent application 
was filed in 2016 
for the combination 
www.anavex.com 
PD PRE 084 Sig-1R agonist PD mouse model (6-OH 
DOPA lesion) 
[116] - - 
Cutamesine  
(SA 4503) 
Sig-1R agonist ALS mouse model 
SOD1 (G93A) model 
+NSC34motoneuron 
cells 
SOD1 (G93A) mouse 
[139] 
[140] 
[140] 
[102] 
- - ALS 
PRE-084 Sig-1R agonist wobbler mouse [115] - - 
PRE-084 Sig-1R agonist PC63 cells [141, 142] - - HD 
Pridopidine Sig-1R agonist, 
DA stabilizer 
HD mouse model [144, 145] - - 
TBI  
traumatic 
brain injury 
PPBP Sig-1R agonist TBI neonatal mouse 
model 
[154, 155] - - 
Retinal 
ganglion cell 
death 
(+) Pentazocine Sig-1R agonist Murine retinal cells 
RGC-5 cells 
[157, 158] - - 
Ischemic 
stroke 
Cutamesine 
(SA4503) 
Sig-1R agonist - - Phase-2 trial [156] 
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AD patients decreased level of Sig-1R was demonstrated 
[74, 119, 120]. 
 Drugs activating Sig-1R are considered to be antiamnes-
tic and neuroprotective in NDDs such as AD. Several Sig-1R 
agonists (e.g. afobazole) protected cultured neurons against 
Aβ 25-35 toxicity [121, 122]. The same agonists attenuated 
learning and memory deficits observed in mice after intra-
cerebroventricular injection of Aβ 25-35 [59]. 
 Very recently, a mixed muscarinic-1 (M1) and Sig-1R 
agonist (AF710B, 1-(2,8-Dimethyl-1-thia-3,8-diazaspiro(4,5) 
dec-3-yl)-3-(1H-indol-3-yl)propan-1-one) has been used in 
AD mouse models. AF710B protects synapses via concomi-
tant activation of the Sig-1R and a super-sensitive M1R, via 
a hypothetical complex of M1R-Sig-1R [123]. 
 Anavex 2-73 (Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-
furanmethanamine hydrochloride), an agonist of the intracel-
lular Sig-1 chaperone protein is also a mixed ligand for 
sigma1/muscarinic receptors. It has been reported to bind to 
Sig-1 receptor in the high nanomolar and the muscarinic 
receptor in the low micromolar range. Anavex2-73 was 
shown to block tau-hyperphosphorylation and Aβ 1-42 gen-
eration in the Aβ 25-35 injection mouse model of AD [124] 
and protected mitochondria [125]. The latest studies in this 
mouse model demonstrated that the combination of Sig-1R 
agonists with donepezil showed a synergic protective effect 
[126], that is Sig-1R drugs offer a neuroprotective potential, 
also in combination with other therapeutic agents (e.g. with 
donepezil). Anavex Plus is a promising, potentially novel 
combination drug for AD, filed for patent application. It 
combines Anavex 2-73 Plus donepezil (Aricept), the best-
selling AD drug. The combination drug produced up to 80% 
greater reversal of memory loss and neuroprotection com-
pared to the administration of its individual counterparts. A 
patent application has been filed for Anavex Plus by the 
company. 
 According to its website (www.anavex.com), Anavex 
conducted a Phase 1 clinical trial in healthy men and Ger-
many, which showed a maximum tolerated dose of 55 mg. 
The company completed a Phase 2a trial with Anavex 2-73 
to compare oral and intravenous doses in people with mild to 
moderate AD at the end of 2016. Thereafter, the company 
plans to initiate a Phase 2/3 trial with the compound enroll-
ing up to 300 mild to moderate AD patients. 
 The mechanism of Sig-1R mediated neuroprotective and 
anti-amnestic effects are not fully understood, but may in-
clude regulation of Ca2+ [121], modulation of Bcl-2 and 
caspase levels [127] and attenuation of oxidative stress 
[128]. 
 The protective role of Sig-1R activation in AD is yet un-
der discussion. In heterogeneous knock-out mice the Sig-1R 
deficiency reduced Aβ 25-35 induced hippocampal neuron 
death and cognitive deficits [129]. Sig-1R deficiency or 
blockade can reduce Aβ enhanced Ca2+-influx and prevent 
neurotoxicity [130]. The discrepancy in the scientific litera-
ture is hard to be reconciled, perhaps exact timing of Sig-1R 
activation might explain the contradictory effects. Although 
preclinical evidences suggest that Sig-1R agonists might be 
useful in treating AD, no selective Sig-1R agonist is  
currently available for clinical use. 
9.2. Parkinson’s Disease 
 Likewise in Alzheimer’s disease [74] Sig-1Rs are down-
regulated in the brains of early stage PD patients [75, 131]. 
Recently, the pharmacological stimulation of the Sig-1R has 
shown some neurorestorative effects in experimental PD 
[116], the treatment of mice with the Sig-1R agonist PRE-
084 caused both behavioral and histological improvements 
in the 6-hydroxydopamine-lesion mouse model of PD. Daily 
treatment of mice with 0.3 mg/kg PRE-084 during 5 weeks 
improved forelimb use, together with a modest recovery of 
dopamine levels. PRE-084 as Sig-1R agonist also upregu-
lated the neurotrophic factors BDNF and GDNF and acti-
vated the trophic factor mediators ERK1 and ERK2 [116]. 
These results show that the restoration of synaptic connec-
tivity correlates with the functional recovery in PD. As in-
flammation contributes to the pathophysiology of PD, the 
attenuation of M1 microglial response by PRE-084 treatment 
supports neuronal recovery in the PD mouse model. In vitro 
experiments where wild type and Sig-1R knock down CHO-
cells were treated with dopamine suggest that Sig-1Rs are 
important endogenous substrates that counteract the dopa-
mine cytotoxicity [132]. The results show that the Sig-1R-
NF-κB-Bcl-2 pathway plays a crucial role against dopamine 
induced apoptosis. 
9.3. Amyotrophic Lateral Sclerosis (ALS) and Fronto-
temporal Lobe Dementia (FTLD) 
 ALS is characterized by the progressive loss of motoneu-
rons in the brainstem, motor cortex and spinal cord causing 
paralysis and death. Pathological hallmarks include calcium 
dysregulation and cytotoxicity, ER-stress and mitochondrial 
dysfunction [133], accumulation of misfolded proteins, 
neuro-inflammation and degradation of motoneurons [102]. 
It was demonstrated that a loss of Sig-1R is causative for a 
juvenile form of ALS (ALS16) and collapse of MAM is a 
common pathomechanism in both Sig-1R and SOD-1 linked 
ALS [134]. Mutations in the Sig-1R gene were found in pa-
tients with FTLD-ALS and a juvenile form of ALS [79, 
135]. The receptor mutation lies very close to an area of 
chromosome 9, called the ALS-FTLD locus, which re-
searchers have linked to ALS and FTLD [136]. A significant 
reduction of Sig-1R protein level was found in the lumbar 
spinal cord of ALS patients [137]. Aberrant modifications of 
Sig-1R ((abnormal accumulation in ER structures, enlarged 
C-terminals) were found in α motoneurons during the patho-
genesis of ALS [137]. Since Sig-1R can regulate ERAD 
[138], this Sig-1R accumulation and co-localization with 
aberrant protein assemblies may reflect a compensatory ef-
fort by Sig-1R to clear misfolded proteins in ALS. 
 Attempts to target Sig-1Rs to treat ALS gave promising 
results in model experiments both in vitro and in vivo. The 
protective role of Sig-1R in motoneurons of an ALS mouse 
model has been confirmed [139]. SA4503, a Sig-1R agonist 
suppressed motor neuron damage in model experiments, 
both in vitro (NSC34 motor neuron cells) and in vivo (in the 
SOD1 (G93A) mouse model) [140]. PRE-084 treatment pro-
longed life span and slowed the progression of ALS symp-
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toms in a SOD1 (G93A) mouse model of ALS [102]. Chronic 
(8 weeks) PRE-084 treatment (0.25 mg/kg, i.p., three times a 
week) improved motoneuron survival and locomotor per-
formances in the wobbler mouse, an animal model of spon-
taneous motoneuron degeneration [115]. Experimental re-
sults suggest that targeting Sig-1R with agonists may help 
ameliorate protein aggregation and slow disease progression 
by enhancing the chaperone activity of Sig-1R. 
9.4. Huntington Disease (HD) 
 HD is a “polyglutamine” (polyQ) disease, a genetic dis-
order: an autosomal dominant mutation in the huntingtin 
gene by a repetitive CAG region. HD is characterized by 
progressive motor and cognitive deficits resulted by selective 
neuronal loss. 
 Recent studies in the neuronal HD model (the cell line 
PC6.3) showed decreased Sig-1R levels in the presence of a 
mutant huntingtin protein expression (containing 120 glu-
tamine repeats, 120 polyQ or 120Q huntingtin, [141]. Ad-
ministration of PRE-084 to the mutant PC6.3 cells restored 
the deficits in Sig-1R protein levels caused by the mutant 
huntingtin expression, probably by modulation of post-
transcriptional processes [141]. PRE-084 also promoted cell 
viability and decreased caspase-3 and caspase-12 (an ER 
resident caspase) cleavage, probably by attenuation of ER 
stress through the activation of Sig-1R. PRE-084 can per-
form neuroprotection also by modulation of the calpas-
tatin/calpain system [142] which positively affects NF-κB 
signaling to upregulate various cellular antioxidants and de-
crease ROS levels [141]. 
 Sig-1R is involved in degradation of intranuclear inclu-
sions in a cellular model of HD [143]. 
 A registered drug, pridopidine, originally described as a 
dopamine stabilizer, improves HD motor symptoms as 
measured in clinical trials. Binding studies shows that Sig-
1R is a high affinity receptor for pridopidine: the compound 
is also a Sig-1R agonist. HD mouse model experiments 
demonstrate that Sig-1R mediates the beneficial effect of 
pridopidine by preventing spine loss of striatal medium spiny 
neurons in HD [144]. Activation of Sig-1R and the subse-
quent upregulation of BDNF pathway represents the core 
component of the mode of action of pridopidine (promoting 
neuronal plasticity and survival) [145]. 
9.5. Traumatic Brain Injury 
 Traumatic brain injury (TBI) is one of the leading acute 
neurological disorders causing death and disability world-
wide [146]. Very few effective treatments are available to 
mitigate neuronal damage and patients need long term care 
for physical and psychosocial rehabilitation. The outcome 
and costs of treatment after TBI are difficult to predict due to 
the physical disability combined the emotional and psycho-
social consequences of the trauma [147]. The high rate of 
blast-related TBIs resulting from current combat operations 
profoundly affects the health and quality of life of service 
members and veterans during times of both war and peace. 
 Physical trauma to the brain initiates a series of inflam-
matory reactions, which includes release of intracellular 
products from damaged cells, microglia activation, cytokine 
production, and recruiting peripheral inflammatory cells into 
damaged areas. Microglia function is critical in response to 
brain injury [148]. Upon activation, microglia undergoes 
morphological transformation, secretes inflammatory media-
tors, and clears tissue debris by phagocytosis [149]. How-
ever, activated microglia can aggravate brain injury and im-
pair its restoration [150]. A cumulative evidence suggests 
that activated microglia can release pro-inflammatory cyto-
kines (e.g., TNF-α) and nitric oxide, which extend the neu-
ronal injury after TBI [151]. Therefore, inhibition of micro-
glial activation can protect brain tissue from the sequalae of 
TBI [152], and can be an important element of therapeutic 
approaches against TBI. Chronic microglial responses may 
be responsible for neurodegeneration in many neurological 
disorders and the role of Sig-1Rs might be to “switch-off” 
microglia after they responded to an injury allowing for mi-
croglial cells to leave site of damage [153]. 
 Considering the presence of Sig-1R on microglial cells 
[11] and the effects Sig-1R agonists on reducing microglia 
activation [102], it was postulated and recently confirmed 
that activation of Sig-1R receptors after TBI can reduce le-
sion volume, lessen brain edema, and attenuate neurological 
deficits [154]. The Sig-1R agonist PPBP (4-phenyl-1-(4-
phenylbutyl)piperidine) protects brain against newborn exci-
totoxic brain injury in an established neonatal mouse model 
by inhibiting microglial activation in vivo [155]. 
9.6. Other Diseases 
 Sig-1R agonists have been tried in animal models of dif-
ferent disorders and also used for the treatment of different 
diseases. Thus, cutamesine (SA4503) was used for recovery 
enhancement after ischemic stroke [156]. (+)-Pentazocine 
reduced NMDA-induced retinal ganglion cell death: recently 
Sig-1R is a promising therapeutic target for retinal neurode-
generative disorders [157, 158]. 
10. DIMETHYLTRYPTAMINE AS A NATURAL SIG-
1R LIGAND 
 The discovery of the tryptamine analogue DMT as a 
natural ligand of the Sig-1R has moved the 40-year long 
fuzzy history of both of these molecules toward clarification. 
DMT was classified as an endogenous hallucinogen [159, 
160] with exact physiological function unclear [161]. Aya-
huasca, a psychoactive Amazonian ethnomedicinal brew, 
raised increased scientific and public interest during the last 
two decades. Ayahuasca is prepared from two admixture 
plants (Banisteriopsis caapi and Psychotria viridis) the latter 
provides the psychoactive alkaloid DMT [162, 163]. More 
than 40 years of research has proven to be insufficient to 
provide a proper neurobiological description for the role of 
DMT as endogenous hallucinogen. This was in part due to a 
paradigm problem in which DMT has been primarily studied 
in terms of being “hallucinogen” since it has been known to 
produce false perceptions. These effects presumably reflect 
action on serotonin (5-HT) receptors (5-HT1A, -2A and -2C) 
[164], and very probably involve the metabotropic glutamate 
receptors [165]. However, the Sig-1R action of DMT may 
turn out to be more revealing and more relevant for its 
physiological function. The main ingredients of the ayahua-
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sca are DMT and the β-carboline derivative alkaloid harmine 
[166]. It is reasonable to suppose that DMT from this exoge-
nous source can exert Sig-1R agonist effect and mitigate a 
wide variety of problems related to the disorganized web of 
mitochondrial dysfunction, ER stress, and UPR. 
 DMT is considered as a natural ligand of the Sig-1R [3]. 
It is assumed that the Sig-1R might be involved in the DMT-
induced psychedelic effects [167]; however, this is probably 
not so, since many drugs—typically non-hallucinogens—
bind to the Sig-1R with higher affinity than DMT. Another 
vista has been opening up instead. If the Sig-1R mitigates 
ER stress [71], promotes neuronal survival against oxidative 
stress [70], and regulates immune processes [168], one may 
attribute the same role to DMT [169]. Since the Sig-1R is 
also known to regulate morphogenesis of neuronal cells, 
such as neurite outgrowth, synaptogenesis, and myelination 
[170]; neurorestorative effects are reasonably expected from 
DMT. In a recent paper [169] Frecska et al. concluded that 
the function of DMT may extend central nervous activity 
and involve a more universal role in cellular protective 
mechanisms. These authors provided converging evidence 
that the role of DMT can be conceptualized along the line of 
adaptive mechanisms like neuroprotection, and immunity. 
The theoretical work was followed by experimental studies 
and Sig-1R mediated anti-inflammatory [80] and anti-
hypoxia effects [171] of DMT were verified in vitro. 
CONCLUSION 
 Sig-1R is an intracellular receptor acting as ER-
chaperone (residing in the MAM) with unique pharmacol-
ogical profile. It has also a unique amino acid sequence and 
steric structure among the receptor proteins. DMT is the en-
dogenous ligand of Sig-1R. Oligomerization and transloca-
tion from the MAM to different biological membranes are 
key functional properties . The receptor has versatile cellular 
function and binds ligands of very diverse structure. Sig-1R 
is a ligand-regulated molecular chaperone which is not cou-
pled to G-proteins. The main physiological functions (modu-
lation of Ca2+ signaling, inhibition of voltage-dependent K+ 
channels, release of various neurotransmitters, immuno-
modulation) are known, however, the signal transduction 
pathways are not yet clarified. 
 Sig-1R is a pluripotent modulator of cellular events, 
regulating the inter-organelle communication and cell sur-
vival by increasing stress-response signaling. The receptor 
can interact with many proteins (with diverse structure and 
function) and can form oligomeric assemblies and heterodi-
mers with other proteins. The existence of different oli-
gomeric forms might provide a wide adaptability, which 
enables Sig-1R to interact with structurally different sub-
strates. 
 Many marketed psychotropic drugs (fluvoxamine, done-
pezil) have affinity on Sig-1R, however, the mechanism of 
action is not yet clear. Receptor binding affinity and pharma-
cological activities frequently do not show good correlation, 
the molecular basis of ligand efficacy is to be discovered. 
Although Sig-1R agonists show neuroprotective effect in 
cellular and animal models, no effective registered neuropro-
tective drugs are on the market. Sig-1R agonists would be 
ideal drug candidates for translational medicine, because the 
known ligands have limited side effects: their modulatory 
action starts only under pathological conditions. A further 
work is required for clarifying the cellular mechanisms and 
molecular targets of Sig-1R. Application of Sig-1R agonists 
alone, very probably, will not be sufficient for the treatment 
of neurodegenerative diseases. 
LIST OF ABBREVIATIONS 
AChE = Acetylcholine esterase 
AD = Alzheimer’s disease 
ALS = Amyotrophic lateral sclerosis 
ASK = Apoptosis signal-regulating kinase  
ATF6 = Activating transcription factor 6 
ATP = Adenosine triphosphate 
BACE = Beta-site APP cleaving enzyme 
Bak = Bcl-2 homologous antagonist killer 
Bax = Bcl-2 like protein 4  
Bcl-2 = B-cell lymphoma 2 
BiP = Binding immunoglobulin protein 
BDNF = Brain derived neurotrophic factor 
CNS = Central nervous system 
DMT = Dimethyltryptamine  
DTG = 1,3-Di-o.tolyl guanidine 
ER = Endoplasmic reticulum 
ERAD = ER-associated degradation 
ERG2 = Yeast sterol isomerase 
ERK = Extracellular signal regulated kinases 
FTLD = Frontotemporal lobar degeneration 
FRET = Forster resonance energy transfer 
GDNF = Glial cell-derived neurotrophic factor 
GFAP = Glial fibrillary acidic protein 
GPCR = G-protein coupled receptors 
GSK3B = Glycogen synthase kinase 3b 
GTP = Guanosine triphosphate 
HD = Huntington disease 
IRE1 = Inositol requiring enzyme 1 
IP3R = Inositol-triphosphate receptor 
ID = Intrinsically disordered  
JNK = c-Jun amino terminal kinase 
MAM = Mitochondrion associated ER-membrane 
M1R = Muscarinic-1 receptor 
NDD = Neurodegenerative diseases 
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NFkB = Nuclear factor-kappa B 
NMDA = N-methyl-D-aspartate 
Nrf2 = NF-E2-related nuclear factor 2 
PCP = Phencyclidine 
PD = Parkinson’s disease 
PERK = Protein kinase RNA like ER-kinase 
PM = Plasma membrane 
ROS = Reactive oxygene species 
Sig-1R = Sigma-1 receptor 
Sig-2R = Sigma-2 receptor 
SOD = Superoxide dismutase 
TBI = Traumatic brain injury 
TNFa = Tumor necrosis factor a 
UPR = Unfolded protein response 
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